Bendazac
As of the edition of 20 October 2026, Bendazac is a small molecule: withdrawn from the market in 1993; acts on XDH.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Withdrawn from market, 1993
- Kind
- Small molecule
- Withdrawn from market
- 1 January 1993 (in some regions)
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| XDH | Xanthine dehydrogenase/oxidase [Includes: Xanthine dehydrogenase | P47989 |